Q301--INTENT TO SOLE SOURCE NOTICE Nodify Lung Nodule Risk Assessment composed of CDT and XL2 Tests

Network Contracting Office (NCO) 23, Department of Veterans Affairs intends to award a firm fixed price, sole source, single award IDIQ to Biodesix INC for reference laboratory testing utilizing the Nodify Lung Nodule Risk Assessment composed of CDT and XL2 tests for the VISN 23 VA Health Care System. The proposed procurement is to establish a single award IDIQ providing the Nodify Lung Nodule Risk Assessment composed of CDT and XL2 testing to aid pneumologists with identifying patients with high risk to develop cancer of lung and to keep in surveillance those with low genomic profile, avoiding and reducing unnecessary biopsy or surgery procedures, and ensuring the patient get the right surgery at right time reducing the waste of resources. Market research shows no other entity provides Nodify Lung Nodule Risk Assessment composed of CDT and XL2 tests. The intended sole source award to Biodesix INC is in accordance with 41 U.S.C. 1901 as implemented by way of the procedures outline in the Federal Acquisition Regulation (FAR) subpart 13.5. This Sole Source is authorized under FAR subpart 13.106-1(b) - soliciting from one source if the contracting officer determines that the circumstances of this contract action deems only one source reasonably available. This is not a request for competitive offers, quotes, or capability statements. No solicitation will be posted as a result of this notice. This notice complies with FAR 5.101. This Special Notice is being issued for information purpose only. The formal Justification & Approval for this action shall be posted on this site in accordance with FAR Part 6.305(a) within 14 days after final award. NAICS: 621511 SBA Size Standard: $35 million PSC: Q301